These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 8497207)

  • 21. Immunopharmacokinetics of 111In-CYT-103 in ovarian cancer patients.
    Jusko WJ; Kung LP; Schmelter RF
    Targeted Diagn Ther; 1992; 6():177-90. PubMed ID: 1576345
    [No Abstract]   [Full Text] [Related]  

  • 22. Planar, SPET and three-dimensional immunoscintigraphy of suspected recurrent colorectal cancer using 111In-B72.3 (Oncoscint CR-OV): effect of administered activity.
    Perkins AC; Vincent RM; Wastie ML; Denton GW; Amar S; Hardcastle JD
    Nucl Med Commun; 1994 Dec; 15(12):981-90. PubMed ID: 7715898
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Radiation absorbed dose estimates for indium-111-labeled B72.3, an IgG antibody to ovarian and colorectal cancer: MIRD dose estimate report No. 18.
    Mardirossian G; Brill AB; Harwood SJ; Olsen J; Dwyer KA; Siegel JA
    J Nucl Med; 1998 Apr; 39(4):671-6. PubMed ID: 9544680
    [No Abstract]   [Full Text] [Related]  

  • 24. In-111 CYT-103 immunoscintigraphy of isolated splenic metastasis from ovarian carcinoma.
    Nguyen BD; Regan F
    Clin Nucl Med; 1997 Apr; 22(4):256-7. PubMed ID: 9099487
    [No Abstract]   [Full Text] [Related]  

  • 25. 111In-CYT-103 scanning in recurrent colorectal cancer--does it affect standard management?
    Dominguez JM; Wolff BG; Nelson H; Forstrom LA; Mullan BP
    Dis Colon Rectum; 1996 May; 39(5):514-9. PubMed ID: 8620800
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Use of OncoScint scan to assess resectability of hepatic metastases from colorectal cancer.
    Su WT; Brachman M; O'Connell TX
    Am Surg; 2001 Dec; 67(12):1200-3. PubMed ID: 11768830
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Immunoscintigraphy of prostatic cancer].
    Aliaev IuG; Vinarov AZ; Rapoport LM; Bezrukov EA; Butnaru DV
    Urologiia; 2006; (4):67-9. PubMed ID: 17058687
    [No Abstract]   [Full Text] [Related]  

  • 28. Indium-111 monoclonal antibody B72.3 scintigraphy in colorectal cancer. Correlation with computed tomography, surgery, histopathology, immunohistology, and human immune response.
    Winzelberg GG; Grossman SJ; Rizk S; Joyce JM; Hill JB; Atkinson DP; Sudina K; Anderson K; McElwain D; Jones AM
    Cancer; 1992 Apr; 69(7):1656-63. PubMed ID: 1551051
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A practical approach to planar and SPECT imaging of 111In-CYT-103.
    Collier BD; Trembath LA; Liu Y; Turoglu HT; Patel N; Thakur S
    Targeted Diagn Ther; 1992; 6():191-210. PubMed ID: 1576346
    [No Abstract]   [Full Text] [Related]  

  • 30. Monoclonal antibody imaging of colorectal and ovarian cancer.
    Haseman MK
    West J Med; 1994 Oct; 161(4):412. PubMed ID: 7817555
    [No Abstract]   [Full Text] [Related]  

  • 31. In-111 CYT-103 immunoscintigraphy in the imaging of ovarian carcinoma.
    Neal CE; Baker MR; Hilgers RD; Fanning J; Burke RC; Snodgrass J; Cull RD
    Clin Nucl Med; 1993 Jun; 18(6):472-6. PubMed ID: 8319398
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunoscintigraphy using 111InCyt103 prior to second look laparotomy in ovarian cancer. A pilot study.
    Hempling RE; Piver MS; Baker TR; Bakshi S; Gilani SS
    Am J Clin Oncol; 1994 Aug; 17(4):331-4. PubMed ID: 8048395
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Indium-111 satumomab pendetide: the first FDA-approved monoclonal antibody for tumor imaging.
    Bohdiewicz PJ
    J Nucl Med Technol; 1998 Sep; 26(3):155-63; quiz 170-1. PubMed ID: 9755434
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Radioimmunoscintigraphy of colorectal carcinomas with three different radiopharmaceuticals.
    Obradovic V; Artiko V; Petrovic M; Lausevic Z; Stojkovic M; Sobic-Saranovic D; Petrovic N; Vlajkovic M; Krivokapic Z
    Neoplasma; 2006; 53(5):444-9. PubMed ID: 17013541
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lipomas as a potential cause for uptake of In-111 MAb72.3 (Oncoscint CR).
    Sakow NK; Japanwalla M; Tuckson WB; Shields RE
    Clin Nucl Med; 1996 Apr; 21(4):332-3. PubMed ID: 8925626
    [No Abstract]   [Full Text] [Related]  

  • 36. Radioimmunoguided surgery of colorectal carcinoma with an 111In-labelled anti-TAG72 monoclonal antibody.
    Muxi A; Pons F; Vidal-Sicart S; Setoain FJ; Herranz R; Novell F; Fernandez RM; Trias M; Setoain J
    Nucl Med Commun; 1999 Feb; 20(2):123-30. PubMed ID: 10088160
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cancer patients benefit from monoclonal imaging.
    Neal CE
    Diagn Imaging (San Franc); 1993 Jun; 15(6):92-7. PubMed ID: 10148791
    [No Abstract]   [Full Text] [Related]  

  • 38. Pretargetted imaging of colorectal cancer recurrences using an 111In-labelled bivalent hapten and a bispecific antibody conjugate.
    Chetanneau A; Barbet J; Peltier P; Le Doussal JM; Gruaz-Guyon A; Bernard AM; Resche I; Rouvier E; Bourguet P; Delaage M
    Nucl Med Commun; 1994 Dec; 15(12):972-80. PubMed ID: 7715897
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intense uptake of In-111 satumomab pendetide in an inflammatory mass.
    Silberstein EB; Saeks E
    Clin Nucl Med; 1996 Jan; 21(1):53-5. PubMed ID: 8741891
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ovarian cancer: comparison of findings with perfluorocarbon-enhanced MR imaging, In-111-CYT-103 immunoscintigraphy, and CT.
    Low RN; Carter WD; Saleh F; Sigeti JS
    Radiology; 1995 May; 195(2):391-400. PubMed ID: 7724757
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.